Speaker
Description
Molecular imaging in nuclear medicine, based on radiopharmaceuticals, enables the diagnosis and evaluation of major diseases at the molecular level. The development and translation of radiopharmaceuticals driven by clinical needs represent the essence of nuclear medicine advancement. Existing radiopharmaceuticals, such as 18F-FDG, hailed as the "Molecule of the Century," play a critical role in the precise diagnosis of malignant tumors, cardiovascular, and cerebrovascular diseases. However, there remains a need to develop diverse molecular probes to meet clinical demands and expand the clinical applications of existing probes. Focusing on the development, translation, expansion, and innovation of radiopharmaceuticals is the future path for the advancement of molecular nuclear medicine.
